Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIpepTolDC Vaccine in Type 1 Diabetes
NCT04590872Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of proinsulin peptide-pulsed tolerogenic dendritic cells in type 1 diabetes mellitus (T1D), sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 2 years, Apheresis duration up to 2 years and 3 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
proinsulin peptide-pulsed tolerogenic dendritic cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04590872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590872.